DE69931749D1 - Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff - Google Patents

Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff

Info

Publication number
DE69931749D1
DE69931749D1 DE69931749T DE69931749T DE69931749D1 DE 69931749 D1 DE69931749 D1 DE 69931749D1 DE 69931749 T DE69931749 T DE 69931749T DE 69931749 T DE69931749 T DE 69931749T DE 69931749 D1 DE69931749 D1 DE 69931749D1
Authority
DE
Germany
Prior art keywords
specific
patient
white blood
impstoff
blood cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69931749T
Other languages
English (en)
Other versions
DE69931749T2 (de
Inventor
C Popescu
Lawrence Boni
J Robb
M Batenjany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomira USA Inc
Original Assignee
Biomira USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira USA Inc filed Critical Biomira USA Inc
Publication of DE69931749D1 publication Critical patent/DE69931749D1/de
Application granted granted Critical
Publication of DE69931749T2 publication Critical patent/DE69931749T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69931749T 1998-01-16 1999-01-15 Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff Expired - Fee Related DE69931749T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7170298P 1998-01-16 1998-01-16
US71702P 1998-01-16
PCT/US1999/000935 WO1999036085A1 (en) 1998-01-16 1999-01-15 Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Publications (2)

Publication Number Publication Date
DE69931749D1 true DE69931749D1 (de) 2006-07-20
DE69931749T2 DE69931749T2 (de) 2007-05-31

Family

ID=22103016

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931749T Expired - Fee Related DE69931749T2 (de) 1998-01-16 1999-01-15 Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff

Country Status (8)

Country Link
US (3) US6207170B1 (de)
EP (1) EP1045698B1 (de)
JP (1) JP2002509114A (de)
AT (1) ATE328607T1 (de)
AU (1) AU737330B2 (de)
CA (1) CA2318557A1 (de)
DE (1) DE69931749T2 (de)
WO (1) WO1999036085A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP2630968A1 (de) * 2006-06-30 2013-08-28 Baylor Research Institute Mithilfe von GM-CSF und Interfron alpha erzeugte und mit hitzebehandelten und getöteten Krebszellen geladene dendritische Zellen
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
US10107791B2 (en) * 2015-12-01 2018-10-23 Purdue Research Foundation Proteoliposome and production method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816249A (en) 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5194384A (en) 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
CA2246708C (en) * 1996-02-16 2005-06-14 Biomira Usa Inc. Vaccine for b-cell malignancies

Also Published As

Publication number Publication date
JP2002509114A (ja) 2002-03-26
US20020155135A1 (en) 2002-10-24
AU2031899A (en) 1999-08-02
EP1045698A1 (de) 2000-10-25
US6207170B1 (en) 2001-03-27
ATE328607T1 (de) 2006-06-15
EP1045698B1 (de) 2006-06-07
DE69931749T2 (de) 2007-05-31
WO1999036085A1 (en) 1999-07-22
CA2318557A1 (en) 1999-07-22
US20010012517A1 (en) 2001-08-09
AU737330B2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
ATE329672T1 (de) Hämodiafiltration/hämofiltrations-patronen
DE3587139D1 (de) Gewebeimplantat.
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
IL143243A0 (en) A cultured tissue construct containing fibroblast cells and methods for the production thereof
ATE407362T1 (de) Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen
WO2003103745A3 (en) EXPANDABLE BLOOD PUMP AND RELATED METHODS
WO1988002406A3 (en) Methods of regulating metabolic stability of proteins
ATA165999A (de) Medium zur protein- und serumfreien kultivierung von zellen
EP0796040A4 (de) Verfahren und anordnung von beuteln zur konzentrierung weisser zellen
DE68928638D1 (de) Polyethylenglycol (peg)-protein addukte und prozess zu ihrer auftrennung
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
DE69838147D1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ES2053678T3 (es) Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
DK1196566T3 (da) Ekspressionsvektorer og -metoder
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
DE69931749D1 (de) Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff
DE60213852D1 (de) Herstellung von zellsuspensionen
DE69528170D1 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
EP1601687A4 (de) Verfahren zur erhöhung der ausbreitung von b-zellen
ATE73665T1 (de) Blutzellentrennung.
NO20060637L (no) Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater
ATE405291T1 (de) Mittel zur beeinflussung von hyperaktivierten immunologischen effektorzellen
DE60308917D1 (de) Verwendung einer Zusammensetzung enthaltend 5-Androsten-3beta,17alpha-diol
DE3882220D1 (de) Herstellung von chlordioxyd in einer elektrolytischen zelle.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee